Status:

COMPLETED

Hydrolyzed Egg and Tolerance Induction

Lead Sponsor:

Société des Produits Nestlé (SPN)

Conditions:

Allergy

Eligibility:

All Genders

12-66 years

Phase:

NA

Brief Summary

The aim of this trial is to assess the effect of hydrolyzed egg orally administered on oral tolerance induction to egg in children allergic to egg as compared to a placebo.

Eligibility Criteria

Inclusion

  • Child of any ethnicity aged between 12 and 66 months at the time of enrolment
  • Positive Skin Prick Test (SPT) to egg white within the last 3 months
  • Either positive oral challenge OR convincing history, defined as an immediate (\<1h) reaction following isolated ingestion of egg, positive SPT to egg white and positive sIgE (\> 0.35 kU/L) for at least one of the following: egg, egg white, ovalbumin, ovomucoid, within the last 12 months
  • Having obtained his/her signed legal representative's informed consent.

Exclusion

  • History of severe anaphylaxis to egg
  • Significant pre-natal and/or post-natal disease
  • Child on systemic drugs (e.g. antihistamines, beta-agonists, ACE-inhibitors) according to half-life at time of enrolment
  • Congenital illness or malformation that may affect normal growth (especially immunodeficiency)
  • Child whose parents / caregivers cannot be expected to comply with treatment
  • Child currently participating in another interventional clinical trial

Key Trial Info

Start Date :

October 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2014

Estimated Enrollment :

29 Patients enrolled

Trial Details

Trial ID

NCT01526863

Start Date

October 1 2012

End Date

July 1 2014

Last Update

January 16 2015

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

University of Athens

Athens, Greece, 11527

2

University Hospital of Padua

Padua, Italy, 35128

3

Hochgebirgsklinik Davos

Wolfgang, Switzerland, 7265